[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inoperable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inoperable":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100503310",false,"NCT05833594","Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","Anhui Provincial Hospita","Inclusion Criteria:\n\n* 18-85 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-2;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n* initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 85 years old;\n* ECOG\\>2;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n* Resectable at initial diagnosis confirmed by thoracic surgeons;\n* Previous treatment of chemotherapy, radiotherapy, and other treatment;\n* Contraindications for chemoradiotherapy;\n* No signature of inform consent.","ALL","18 Years","85 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.",[24,25,26,27],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy","Immunonutrition","Inoperable","RECRUITING","2023-12-20",{"date":31,"type":32},"2023-12-26","ACTUAL",{"date":34,"type":32},"2023-07-01",{"date":36,"type":20},"2026-12-01",{"name":38,"class":39},"Anhui Provincial Hospital","OTHER_GOV",""]